Improving cardiac differentiation of human pluripotent stem cells by targeting ferroptosis

Area of Science:

• Stem Cell Biology
• Cardiovascular Research
• Regenerative Medicine

Background:

• Human pluripotent stem cells (hPSCs) offer a renewable source for patient-specific cardiomyocytes, crucial for disease modeling and regenerative medicine.
• Current differentiation protocols, often Wnt pathway-dependent, suffer from significant cell loss during initial stages (e.g., GSK-3 inhibition).
• Limited availability of adult cardiomyocytes due to low proliferation and ex vivo viability necessitates efficient stem cell-derived alternatives.

Purpose of the Study:

• To enhance the efficiency of cardiomyocyte generation from hPSCs.
• To identify and mitigate detrimental cell death mechanisms during early in vitro differentiation.
• To improve the robustness and cell yield of the cardiomyocyte differentiation process.

Main Methods:

• Investigated cell death during the initial 48 hours of in vitro cardiomyocyte differentiation from hPSCs.
• Pharmacologically targeted various cell death pathways to identify the predominant mechanism.
• Utilized ferrostatin-1, a ferroptosis inhibitor, during the differentiation process.

Main Results:

• Ferroptosis was identified as the primary mode of cell death during the initial 48 hours of differentiation.
• Inhibition of ferroptosis using ferrostatin-1 significantly reduced cell loss.
• The intervention led to increased robustness and a higher overall yield of cardiomyocytes.

Conclusions:

• Targeting ferroptosis is a viable strategy to improve hPSC-derived cardiomyocyte generation efficiency.
• Ferrostatin-1 treatment enhances cell survival during critical early differentiation phases.
• This approach holds promise for advancing disease modeling and therapeutic applications using patient-specific cardiomyocytes.